Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb trial evaluating the efficacy and tolerability of vaginal telapristone [Proellex-V] in patients with severe menstrual bleeding associated with uterine fibroids

Trial Profile

Phase IIb trial evaluating the efficacy and tolerability of vaginal telapristone [Proellex-V] in patients with severe menstrual bleeding associated with uterine fibroids

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telapristone (Primary)
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Apr 2016 According to a Repros Therapeutics media release, once both - this vaginal and oral (see CTP 242103) studies, complete both 18 week courses of treatment, the company plans to request an end of phase II meeting with the FDA to jointly discuss plans for phase III.
    • 12 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to a Repros Therapeutics media release.
    • 12 Apr 2016 Results published in a Repros Therapeutics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top